See the DrugPatentWatch profile for Omalizumab
What is Omalizumab's Patent Status?
Omalizumab, known by the brand name Xolair, is currently protected by multiple patents. These patents cover various aspects of the drug, including its composition, manufacturing processes, and methods of use. DrugPatentWatch.com tracks these patents, providing detailed information on their status and expiration dates [1].
When Does Omalizumab's Exclusivity Expire?
The exact expiration dates for Omalizumab's patents vary. Some patents are set to expire in the coming years, while others have longer protection periods. For a comprehensive list and specific dates, referring to patent databases like DrugPatentWatch.com is recommended [1].
Can Biosimilars Enter Before Patent Expiry?
Generally, biosimilars cannot enter the market before the relevant patents for the reference biologic drug expire. However, complex legal challenges and patent litigation can sometimes lead to earlier market entry for biosimilars if patents are successfully invalidated or found to be infringed.
How Does Omalizumab Work?
Omalizumab is a monoclonal antibody that targets immunoglobulin E (IgE). By binding to IgE, it prevents IgE from binding to mast cells and basophils, thereby reducing the release of inflammatory mediators that contribute to allergic reactions and conditions like asthma and chronic urticaria [2].
What Conditions is Omalizumab Approved For?
Omalizumab is approved for the treatment of moderate to severe persistent allergic asthma in individuals who have a perennial indoor allergen component. It is also indicated for chronic spontaneous urticaria (CSU) in adults and adolescents who have persistent urticaria requiring additional treatment [2].
Who Manufactures Omalizumab?
Omalizumab was jointly developed by Genentech and Novartis. Genentech is a member of the Roche Group, and Novartis markets the drug in many regions [3].
What are the Potential Side Effects of Omalizumab?
Common side effects of Omalizumab can include injection site reactions, viral infections, upper respiratory tract infections, sinusitis, and headaches. More serious, though rare, side effects can include anaphylaxis. Patients should discuss potential risks with their healthcare provider [2].
Are There Alternative Treatments for Asthma or Urticaria?
Yes, there are alternative treatments available for asthma and chronic urticaria, depending on the severity and specific type of condition. These can include inhaled corticosteroids, bronchodilators, antihistamines, and other biologic therapies [2].
How is Omalizumab Administered and What is the Typical Dosage?
Omalizumab is administered via subcutaneous injection. The dosage and frequency of administration are determined by a patient's IgE level and body weight, typically ranging from 150 mg every four weeks to 375 mg every two weeks [2].
What is the Cost of Omalizumab?
The cost of Omalizumab can be significant, as is common with biologic medications. Pricing can vary based on insurance coverage, geographic location, and specific treatment regimens. Patient assistance programs may be available to help offset costs [4].
What is the Future of Omalizumab and its Competitors?
The market for biologic treatments for allergic diseases and urticaria is competitive and evolving. As patents approach expiration, the potential for biosimilar competition increases, which could impact pricing and market dynamics. Ongoing research may also lead to new indications or improved formulations of Omalizumab or similar therapies [1].
Sources
1. DrugPatentWatch.com
2. Genentech and Novartis product information (as publicly available)
3. Company press releases and investor relations (Genentech/Roche and Novartis)
4. Pharmaceutical pricing databases and market analysis reports (general industry knowledge)